SGEN - Seattle Genetics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
69.18
-1.62 (-2.29%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close70.80
Open70.95
Bid68.00 x 1200
Ask69.18 x 3200
Day's Range68.45 - 72.00
52 Week Range47.75 - 84.37
Volume1,552,352
Avg. Volume878,879
Market Cap11.135B
Beta (3Y Monthly)2.28
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Were Hedge Funds Right About Buying Seattle Genetics, Inc. (SGEN)?
    Insider Monkey2 days ago

    Were Hedge Funds Right About Buying Seattle Genetics, Inc. (SGEN)?

    "October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]

  • Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know
    Zacks2 days ago

    Will Seattle Genetics (SGEN) Report Negative Earnings Next Week? What You Should Know

    Seattle Genetics (SGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Seattle Genetics's (NASDAQ:SGEN) 111% Share Price Increase Well Justified?
    Simply Wall St.9 days ago

    Is Seattle Genetics's (NASDAQ:SGEN) 111% Share Price Increase Well Justified?

    The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But if you buy shares in a really great company, you can more than double your money. To wit, the Seattle Genetics, Inc. (NASDAQ:SGEN...

  • Seattle Genetics' Adcetris Progresses Well Amid Competition
    Zacks9 days ago

    Seattle Genetics' Adcetris Progresses Well Amid Competition

    Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.

  • GuruFocus.com10 days ago

    5 Oncology Companies That Are Set to Run

    The cancer treatment market is a massive one, and the companies that produce these treatments often make strong investment opportunities. With so much financial opportunity in the space and several areas with medical need, oncology stocks tend to be met with heavy investor interest. Warning! GuruFocus has detected 6 Warning Signs with SGEN.

  • Markit11 days ago

    See what the IHS Markit Score report has to say about Seattle Genetics Inc.

    Seattle Genetics Inc NASDAQ/NGS:SGENView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate * Economic output in this company's sector is expanding Bearish sentimentShort interest | NeutralShort interest is moderate for SGEN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $1.17 billion over the last one-month into ETFs that hold SGEN are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher
    Zacks12 days ago

    Seattle Genetics (SGEN) Surges: Stock Moves 7.6% Higher

    Seattle Genetics (SGEN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

  • Seattle Genetics Closes Enrollment in Cervical Cancer Study
    Zacks19 days ago

    Seattle Genetics Closes Enrollment in Cervical Cancer Study

    Seattle Genetics (SGEN) and partner Genmab end enrollment in the phase II study on tisotumab vedotin for treating patients with advanced/metastatic cervical cancer.

  • Seattle Genetics, Astellas Report Positive Cancer Study Data
    Zacks22 days ago

    Seattle Genetics, Astellas Report Positive Cancer Study Data

    Seattle Genetics (SGEN) and partner Astellas present positive top-line data from the first cohort of a phase II study on enfortumab vedotin for treating patients with advanced/metastatic urothelial cancer.

  • This Biotech Stock Toppled Despite Success In Bladder Cancer Study
    Investor's Business Daily23 days ago

    This Biotech Stock Toppled Despite Success In Bladder Cancer Study

    Seattle Genetics stock initially approached a breakout Thursday after its bladder cancer treatment outperformed expectations in a test. But shares fell into the red at the closing bell.

  • Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound?
    Zackslast month

    Seattle Genetics (SGEN) Down 6.1% Since Last Earnings Report: Can It Rebound?

    Seattle Genetics (SGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • GuruFocus.comlast month

    ImmunoGen Failure Casts a Shadow on Antibody-Drug Conjugates

    Flagship ImmunoGen (IMGN) ovarian cancer drug candidate Mirvetuximab Soravtansine just failed to meet its primary endpoint in Phase III studies. The failed candidate is an antibody-drug conjugate (ADC), a drug model that uses an antibody as a homing device to lock on to cancer cells and deliver a targeted drug payload. The entire ADC approach to cancer treatment could arguably be called into question here.

  • Pullback Strategies: 10 Stocks That Could Fall the Fastest
    Investopedialast month

    Pullback Strategies: 10 Stocks That Could Fall the Fastest

    These stocks are heavily owned by high-turnover hedge funds, and thus are likely to face severe selling pressure once these funds turn bearish.

  • Seattle Genetics, Inc. (NASDAQ:SGEN): Are Analysts Optimistic?
    Simply Wall St.2 months ago

    Seattle Genetics, Inc. (NASDAQ:SGEN): Are Analysts Optimistic?

    Seattle Genetics, Inc.'s (NASDAQ:SGEN): Seattle Genetics, Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. On 31 December 2018, theRead More...

  • Seattle Genetics' new Bothell campus sells for $63M
    American City Business Journals2 months ago

    Seattle Genetics' new Bothell campus sells for $63M

    Commercial real estate investors are seeking out opportunities in places like Bothell where prices are lower relative to much of the rest of the Eastside.

  • Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars
    Zacks2 months ago

    Biotech Stock Roundup: Regeneron Impresses in Q4, Gilead Slumps, MacroGenics Soars

    Key highlights of the week were fourth-quarter results from Regeneron Pharmaceuticals and Ligand Pharmaceuticals along with other regulatory and pipeline updates.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SGEN earnings conference call or presentation 7-Feb-19 9:30pm GMT

    Q4 2018 Seattle Genetics Inc Earnings Call

  • Seattle Genetics' Adcetris Gets EC Nod for Label Expansion
    Zacks2 months ago

    Seattle Genetics' Adcetris Gets EC Nod for Label Expansion

    Seattle Genetics' (SGEN) partner, Takeda Pharmaceutical receives EC approval for Adcetris in combination with AVD to treat adults with previously untreated CD30+ stage IV cHL.

  • Why Goodyear Tire & Rubber, Henry Schein, and Seattle Genetics Slumped Today
    Motley Fool2 months ago

    Why Goodyear Tire & Rubber, Henry Schein, and Seattle Genetics Slumped Today

    Earnings took down some key companies today.

  • Can This Biotech's Only Drug Meet Its 'Multi-Blockbuster Potential'?
    Investor's Business Daily2 months ago

    Can This Biotech's Only Drug Meet Its 'Multi-Blockbuster Potential'?

    Seattle Genetics stock toppled Friday after the biotech met expectations for fourth-quarter sales of cancer treatment Adcetris, but issued soft 2019 guidance for its only approved drug.

  • Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark
    Zacks2 months ago

    Seattle Genetics (SGEN) Q4 Loss Widens, Revenues Top Mark

    Seattle Genetics (SGEN) incurs wider-than-expected loss in Q4 but rides high on revenue beat.

  • Seattle Genetics Looks to Make Adcertis a Blockbuster; Investors Unimpressed
    Motley Fool2 months ago

    Seattle Genetics Looks to Make Adcertis a Blockbuster; Investors Unimpressed

    With shares up 30% year to date, investors may be taking profits.

  • Seattle Genetics (SGEN) Q4 2018 Earnings Conference Call Transcript
    Motley Fool2 months ago

    Seattle Genetics (SGEN) Q4 2018 Earnings Conference Call Transcript

    SGEN earnings call for the period ending December 31, 2018.